[Point Biopharma jumped more than 80% premarket on report of acquisition by Eli Lilly] Eli Lilly is buying Point Biopharma for $12.50 per share in cash, in a deal valued at about $1.4 billion, and the deal is expected to close by the end of 2023. Point Biopharma rose more than 80% before the bell.